Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors
17 11월 2005 - 10:02PM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced the election of
Timothy P. Lynch to its Board of Directors effective November 14,
2005. Mr. Lynch's appointment, which expands the Board of Directors
to eight members, further strengthens the Board in the areas of
financial and operational expertise. Mr. Lynch was also appointed
to serve as a member of the Audit Committee of the Board. Mr. Lynch
has significant experience as a public company executive within the
biotechnology industry and as an investment banker. He currently
serves as a consultant to several early-stage companies in the life
science area. After beginning his career as an investment banker at
Chase Manhattan Bank N.A. and Goldman, Sachs & Co, Mr. Lynch
joined Elan Corporation PLC as Director, Strategic Planning, where
he managed corporate finance and mergers and acquisitions matters.
Mr. Lynch served as Chief Financial Officer of Intermune, Inc. from
1999 to 2002, and as Chief Financial Officer of Tercica, Inc. from
2002 through June 2005. During this time, Mr. Lynch was
instrumental in leading both Intermune and Tercica through their
respective IPOs, and negotiating multiple product license
agreements. Mr. Lynch holds a BA in Economics from Colgate
University and an MBA from Harvard Business School. "We are
delighted that Tim has joined the Allos Board of Directors," said
Michael E. Hart, President and Chief Executive Officer of Allos.
"Tim's financial and operational experience in biotech companies at
similar stages of growth to Allos will be a significant asset to
our future plans for growth." "I'm excited to be part of the Allos
team," said Mr. Lynch. "I look forward to contributing to Allos and
it's future." About Allos Therapeutics, Inc. Allos Therapeutics,
Inc. (NASDAQ:ALTH) is a biopharmaceutical company focused on
developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small
molecule designed to sensitize hypoxic, or oxygen-deprived, tumor
tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, please visit the Company's web site at:
http://www.allos.com/. DATASOURCE: Allos Therapeutics CONTACT:
Jennifer Neiman, Manager, Corporate Communications of Allos
Therapeutics, +1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles